APA (7th ed.) Citation

M, A., J, H., L, A., MG, G., E, B., G, G., . . . L, B. (2026). Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment. Cancer treatment and research communications, 48, 101319. https://doi.org/10.1016/j.ctarc.2026.101319

Chicago Style (17th ed.) Citation

M, Ahrens, et al. "Fumarate Hydratase-deficient Renal Cell Carcinoma - Results of the Exploratory Analysis in the SUNNIFORECAST Trial Comparing Ipilimumab Plus Nivolumab Vs Standard of Care as First Line Treatment." Cancer Treatment and Research Communications 48 (2026): 101319. https://doi.org/10.1016/j.ctarc.2026.101319.

MLA (9th ed.) Citation

M, Ahrens, et al. "Fumarate Hydratase-deficient Renal Cell Carcinoma - Results of the Exploratory Analysis in the SUNNIFORECAST Trial Comparing Ipilimumab Plus Nivolumab Vs Standard of Care as First Line Treatment." Cancer Treatment and Research Communications, vol. 48, 2026, p. 101319, https://doi.org/10.1016/j.ctarc.2026.101319.